Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 101-105

  Jardemark, Kent ^a   Wadenberg, Marie Louise ^a   Grillner, Pernilla ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atypical antipsychotics; Dopamine; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 4' ACETYL N [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BIPHENYL 4 CARBOXAMIDE; 5 [2 [4 (3 FLUOROBENZYLIDENE) 1 PIPERIDINYL]ETHYL] 4 (4 FLUOROPHENYL)THIAZOLE 2 CARBOXAMIDE; 7 (4 FLUOROPHENOXYMETHYL) 2 (5 FLUORO 2 PYRIMIDINYL) 2,3,4,6,7,8,9,9A OCTAHYDROPYRIDO[1,2 A]PYRAZINE; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; APOMORPHINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 4 RECEPTOR BLOCKING AGENT; FANANSERIN; HALOPERIDOL; NAFADOTRIDE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PLACEBO; PNU 170413; RACLOPRIDE; S 33084; SONEPIPRAZOLE; UNCLASSIFIED DRUG; YM 50001; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, HUMAN; DRD4 PROTEIN, HUMAN;

BRAIN; BRAIN CORTEX; CATALEPSY; CLINICAL TRIAL; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC CORTEX; MOTOR DYSFUNCTION; NEUROENDOCRINE DISEASE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; TRANQUILIZING ACTIVITY; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; METABOLISM;

ANIMALS; BRAIN; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA;

EID: 0035987238     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. The case for or against heterogeneity in the etiology of schizophrenia. The genetic evidence
2. The case for heterogeneity in the etiology of schizophrenia
3. The current status of the dopamine hypothesis of schizophrenia
4. The dopamine theory revisited
5. 4 receptors in the action and development of antipsychotic agents
6. 2A receptors in antipsychotic and anticataleptic action
7. 3 receptor in schizophrenia and in antipsychotic drug actions
8. 2 dopamine receptor cDNA
9. 3) as a target for neuroleptics
10. 4 receptor with high affinity for the antipsychotic clozapine
11. 2 receptor mRNA
12. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin
13. 3 receptor in the rat brain
14. Dopamine receptor mRNA expression in human striatum and neocortex
15. 4 receptor: Sequence, gene structure, and demonstration of expression in the cardiovascular system
16. 4 receptors in GABAergic neurons of the primate brain
17. Schizophrenia, the heteromodal association neocortex and development: Potential for a neurogenetic approach
18. Schizophrenia: A neuropathological perspective
19. 3 receptor antagonist, activates locomotion in rodents
20. 3 receptors
21. 3 receptor antagonist
22. 3 receptors as compared with native, rat dopamine D(2) receptors
23. 3 receptors
24. 3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
25. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626
26. 3 receptor
27. 3 preferring antagonist and putative antipsychotic, PNU-170413
28. 2 receptor
29. 4 receptor antagonist
30. 3H]NGD 94-1
31. 4 receptor
32. 4 receptor selective antagonist
33. 4 receptor antagonist
34. 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition
35. 4 receptor antagonist
36. 4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile
37. 3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194
38. 4 receptor antagonist L-745,870 produces antipsychotic-like effects in the presence of a weak dopamine receptor blockade in rats
39. 4 Dopamine Antagonist Group
40. 2A antagonist fananserin in the treatment of schizophrenia
41. 4-receptor antagonist
42. 4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys
43. 3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats
44. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats
45. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways
46. 3 preferring antagonist, and putative antipsychotic, PNU-170413